US Pharma MarketingUltragenyx drug fails pivotal Phase 3, FDA's success at regulating unproven stem cells, and other biotech news patients Physicians rare diseases Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out Reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout Seattle scientists launch $95 million AI biology effort Ultragenyx drug fails pivotal Phase 3, FDA’s success at regulating…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, a crushing Phase 3 failure for Ultragenyx in Angelman syndrome, a new accelerator from Nobel laureate David Baker to use AI to map nature’s design rules, and more.
The sniffly 5-year-old in my bed is coloring a remarkable green-blue rainbow at present. Visionary, truly.
Source: STAT News Pharma